top of page

Our first crowdfunded and crowdsourced study is live & ready to share.

We brought together rheumatoid arthritis (RA) patients and designed a study based on their feedback! Our RA Working Group convened in July and narrowed down their top 5 research ideas. We opened up the voting on Reddit and Twitter, too. The enthusiasm of the community inspired us to continue on our path of citizen science!





To make this possible, we have partnered with Kernls. Kernls has helped scientists and non-profits raise money for their research. One of them being a success story on Long Covid: Patients funded a study that mattered to them, because they weren’t getting the answers they needed.


Crowdfunded studies done by biotech start-ups have the potential to move faster than the traditional academic or industry partners. Our goal with this crowdfunding campaign is to show that people can fund the studies that matter to them, and that we can make them happen in record time.

We discussed the importance of patient-treatment matching with rheumatoid arthritis clinicians. It’s become clear that doctors need better tools for personalizing which drugs they prescribe to their patients.



Visit our crowdfunding page and support in whichever way you can. Fund whichever amount you can budget. Sign up as a “Champion,” so you can amplify the campaign at zero cost. To show that we are committed to this cause, ImYoo is matching donations to our study!


And if rheumatoid arthritis isn’t your cup of tea, stay tuned for our other studies coming soon! They’ll all be posted to our Kernls page and announced in our newsletter (sign up here).


We’re starting with RA, but our campaign represents something much bigger: We’re building a people-driven biodiscovery ecosystem. The best research ideas come from lived experience, so we’re putting the tools in your hands. We envision a future where studies get kickstarted and executed as fast as the people want them. So what are you waiting for? Let’s make that future a reality!

23 views0 comments

We have released a technical note describing ImYoo's experimental platform for performing decentralized immune studies with small samples of capillary blood (0.1-0.5 mL) self collected by participants with the TAP II device from YourBio Health.


The technical note describes technical validation of ImYoo's platform with different data modalities, including single cell and single nuclei RNA-seq, as well as different kinds of input samples, including cryopreserved PBMCs from venous and capillary blood collected using YourBio Health's TAP II device , and nuclei isolated from frozen buffy coat.

A UMAP of a subset of ImYoo's database showing 1M high quality PBMCs consistently processed by ImYoo from fresh blood samples of capillary and venous blood.


Another important experimental result described in the paper is the demonstration that capillary blood gene expression of whole blood samples preserved over 24h on ice is comparable to that of the same samples processed fresh. This is important because preserving samples on ice allows studies to leverage cold-storage shipping rather than having to process samples immediately after collection. Initial results of biological studies performed with ImYoo's platform, including single-point collection and longitudinal sampling are also briefly discussed.


An example of disease specific signatures identified at molecular resolution in capillary blood.



ImYoo continues to search for new clinical research collaborations leveraging this platform, with a focus on autoimmune diseases and understanding immune health, and a focus on experimental designs that leverage the potential for longitudinal sampling and ad-hoc self-sampling by participants at home during adverse events.

15 views0 comments

ImYoo is on track to decentralize immune studies and kickstart research aimed at addressing actionable patient curiosities. We grew our team and launched a revised website: www.imyoo.health!




11 views0 comments
bottom of page